MBRX

Business Context and Reporting Period

Company: Moleculin Biotech, Inc. (MBRX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Moleculin is a late-stage clinical biopharmaceutical company focused on developing "next-generation" anthracyclines and other oncology therapies. Its lead asset, Annamycin (naxtarubicin), is a DNA-binding agent designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) with reduced cardiotoxicity compared to existing therapies. The company relies heavily on licensed intellectual property from MD Anderson Cancer Center and utilizes a mix of internally funded and investigator-initiated (externally funded) clinical trials.

Key Financial Metrics

Note: The 2025 net loss includes significant non-cash items related to warrant liabilities, including a $24.4 million gain from fair value changes and a $31.0 million loss on issuance.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $7.6 million year-over-year. This was primarily driven by non-cash losses associated with the issuance of warrant liabilities ($31.0 million) and transaction costs, partially offset by a non-cash gain from the change in fair value of warrant liabilities ($24.4 million).
• Operating Expenses: Total operating expenses decreased by $1.5 million. R&D expenses declined by $1.8 million due to reduced sponsored research activities, while G&A expenses increased slightly by $0.3 million due to higher regulatory and legal costs.
• Liquidity Position: Cash and cash equivalents increased significantly from $4.3 million to $8.9 million, driven by $27.3 million in net proceeds from financing activities (equity offerings and warrant exercises) compared to $4.6 million in 2024.
• Accounting Policy Change: The company retrospectively changed its accounting policy regarding the classification of certain warrants from liabilities to equity, impacting the presentation of prior period financials and resulting in a reclassification of approximately $16.0 million of warrant liabilities to equity in 2025.

Guidance, Outlook, and Risks

Clinical Outlook and Milestones

• MIRACLE Trial (Annamycin for AML): The pivotal Phase 2B/3 trial is ongoing. Recruitment began in March 2025. The company expects an interim unblinding of data for the first 45 subjects in mid-2026 and a second unblinding for the full 90 subjects in Part A in the second half of 2026.
• Preliminary Data: Blinded preliminary data for the first 30 subjects showed a composite complete remission (CRc) rate of 40% (30% CR, 10% CRi), which the company states substantially outperforms historical outcomes for cytarabine alone in this population.
• Future Trials: Plans include a Phase 1B/2 trial for pancreatic cancer (starting 2026) and pediatric AML trials (planned for 2027).

Liquidity and Capital Resources

• Runway: Management estimates that cash on hand as of December 31, 2025 ($8.9 million), combined with $8.3 million in gross proceeds from financing activities in Q1 2026, will fund operations into the third quarter of 2026.
• Financing Needs: The company explicitly states it will require significant additional funding to complete the MIRACLE trial and continue operations beyond Q3 2026. No commitments for future financing are currently in place.

Key Risks and Contingencies

• Going Concern: The company has incurred an accumulated deficit of $206.0 million and has no revenue. These conditions raise substantial doubt about its ability to continue as a going concern without additional financing.
• Regulatory Approval: Success depends entirely on the outcome of the MIRACLE trial. Failure to meet endpoints or safety issues could halt development.
• Intellectual Property: The company relies on licenses from MD Anderson. Failure to meet milestone payments or development deadlines could result in the loss of these rights.
• Manufacturing: Reliance on single-source contract manufacturers for API and drug product creates supply chain risks.
• Stock Listing: The company recently regained compliance with Nasdaq listing requirements following a reverse stock split in December 2025, but faces ongoing risks of delisting if bid price or equity requirements are not maintained.

Investor Verification Checklist

• Runway Confirmation: Verify the sufficiency of the $17.2 million total cash position (year-end cash + Q1 2026 proceeds) to fund the MIRACLE trial through Q3 2026, given the high burn rate of clinical-stage biotechs.
• Warrant Liability Accounting: Review the impact of the accounting policy change on warrant classification and the volatility of non-cash gains/losses on the income statement.
• MIRACLE Trial Enrollment: Monitor the pace of patient enrollment and the timeline for the mid-2026 interim data readout, as delays could accelerate the need for capital.
• MD Anderson License Obligations: Assess the company's ability to meet upcoming milestone payments and annual license fees to MD Anderson to avoid termination of core IP rights.
• Stock Dilution: Evaluate the dilutive impact of outstanding warrants (over 7.6 million shares) and the recent warrant inducement transactions on existing shareholders.